CAR-T Immunotherapy: Next Generation of Cancer Therapy

'The recent approval of CAR-T therapies has given impetus to the Global T-cell Immunotherapy Market', says RNCOS.
NOIDA, India - March 15, 2018 - PRLog -- Immunotherapy has emerged as an effective tool for cancer treatment since the last few years. Among the different types of immunotherapy approaches, CAR T cell therapy is the first to be approved by the USFDA for the treatment of cancer. These therapies involve the idea of jumpstarting an individual's own immune system to fight cancer. This therapy makes use of genetically engineered T-cells. These T-cells facilitate a more specific and powerful attack for elimination of cancerous cells.

According to the report entitled "Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis", the CAR-T therapy has attracted the attention of biopharmaceutical companies and researchers because of the amazing response they have produced in cancer patients. This therapy offers better specificity, efficacy and improved survival outcomes as compared to traditional oncology therapies. This class of cell based therapies has hit a prime time with the approval of Kymriah and Yescarta for commercial use.

As per RNCOS, latest analysis reports the CAR-T cell therapy has maximum number of candidates in various stages of clinical trials as compared to other adoptive T cell therapies. For instance, KTE-C19 by Gilead Sciences, Inc. is currently in phase II for the treatment of mantle cell lymphoma. Furthermore, CTL019 by Novartis is also in phase II for the treatment of diffuse large B-cell lymphoma. New entrants, such as Cell Medica, Cellectis, Celyad, iCell Gene Therapeutics and Cellular Biomedicine Group among others, are also developing CAR-T therapies which are in early stages of development.

Moreover, according to Healthcare Market Reports, the advancements in technology are driving the development of next generation of CAR T cell therapies. The next generation is intended to expand the impact and improve the safety and efficacy of existing CAR T cell therapies. A particularly exciting development in this field is the use of CRISPR/Cas9 system for the development of CAR T cell therapies from universal donors. All the above mentioned factors are likely to drive the global market for T cell immunotherapy in the coming years.

Feel free to download the sample:

Check Related REPORTS on:


RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

RNCOS E-Services Pvt. Ltd.
G - 199, Sector - 63, Noida – 201301
Email:*** Email Verified
Tags:T-Cell Immunotherapy
Location:Noida - Uttar Pradesh - India
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
RNCOS E-Services Pvt Ltd. News
Most Viewed
Daily News

Like PRLog?
Click to Share